April Global News
The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received ?5 million from Spain's Agencia Espa?ola de Cooperaci?n Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.
April Global News
• The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received €5 million from Spain's Agencia Española de Cooperación Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.
• Thailand's Public Health Minister Chaiya Sasomsap announced that Siriwat Thiptharadon, head of Thailand's Food and Drug Administration, was removed from his position and moved instead to an inactive post. Thiptharadon is known for establishing the former government's compulsory license program, which aimed to make drugs more affordable and is now vulnerable to a committee review under Sasomsap's orders. Chatree Banchuen was named secretary general of Thailand's FDA following Thiptharadon's departure, but resigned a week later citing that he was "uncomfortable with the politics."
• Kampala, Uganda's Mulago Hospital, a 1500-bed facility affiliated with Makerere University, is the home of the first Health Volunteers Overseas (HVO; Washington, DC) hematology training program, created by HVO and the American Society of Hematology (Washington, DC). The program's purpose is to bolster the hematology training of clinicians, lab technicians, technologists, and students.
• The University of Portsmouth (Hampshire, UK) is collaborating with brain tumor charity Brainstrust (Hampshire, UK) among others to create the UK's first dedicated laboratory-based brain tumor research center. Brain tumors are the most common form of cancer in people under 40 and the most common cause of death in children after accidents.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
